Dietary supplementation of inulin alleviates metabolism disorders in gestational diabetes mellitus mice via RENT/AKT/IRS/GLUT4 pathway

Miao Miao†, Yongmei Dai†, Can Rui†, Yuru Fan1, Xinyan Wang1, Chong Fan1, Juan Mu1, Wenwen Hou1, Zhiyong Dong1, Ping Li1*, Guiju Sun2* and Xin Zeng1*

Abstract

Background: Gestational diabetes mellitus (GDM) has significant short and long-term health consequences for both the mother and child. There is limited but suggestive evidence that inulin could improve glucose tolerance during pregnancy. This study assessed the effect of inulin on glucose homeostasis and elucidated the molecular mechanisms underlying the inulin-induced antidiabetic effects during pregnancy.

Method: Female C57BL/6 mice were randomized to receive either no treatment, high-dose inulin and low-dose inulin for 7 weeks with measurement of biochemical profiles. A real-time (RT2) profiler polymerase chain reaction (PCR) array involved in glycolipid metabolism was measured.

Results: Inulin treatment facilitated glucose homeostasis in a dose-dependent manner by decreasing fasting blood glucose, advanced glycation end products and total cholesterol, and improving glucose tolerance. Suppressing resistin (RETN) expression was observed in the inulin treatment group and the expression was significantly correlated with fasting blood glucose levels. The ratios of p-IRS to IRS and p-Akt to Akt in liver tissue and the ratio of p-Akt to Akt in adipose tissue as well as the expression level of GLUT4 increased significantly after inulin treatment.

Conclusions: Our findings indicated improvement of glucose and lipid metabolism by inulin was to activate glucose transport through the translocation of GLUT4 which was mediated by insulin signaling pathway repairment due to decreased expression of RETN and enhanced phosphorylation of IRS and Akt in GDM mice.

Keywords: Gestational diabetes, Fasting blood glucose, Inulin, Glycolysis/gluconeogenesis pathway, RETN

Introduction

Gestational diabetes mellitus (GDM)-defined as hyperglycemia, insulin resistance, and carbohydrate intolerance with the onset or first recognition during pregnancy-is a common obstetric complication, affecting an estimated 15.8% of pregnancies worldwide [1, 2]. GDM women have an increased risk of adverse maternal and perinatal complications, including preeclampsia, hydramnios, increased operative intervention and future type 2 diabetes mellitus, macrosomia [3, 4], congenital anomalies, metabolic abnormalities [5–9], and subsequent childhood and adolescent obesity [10]. In addition, increased levels of inflammatory mediators and biomarkers of oxidative stress can induce maternal insulin resistance, DNA damage, and chromosomal aberrations [11, 12].

This perpetuates an intergenerational cycle of disease that further escalates the obesity epidemic. To break this
cycle, it would be beneficial to generate therapies that prevent GDM from developing [13]. Current treatments include diet and lifestyle interventions, followed by insulin treatment and, in some countries, oral agents such as metformin. Although women are able to maintain adequate glycemic control using these treatment strategies, they can be difficult to implement, and concerns remain regarding the long-term effects of oral agents on the developing fetus. For these reasons, it would be beneficial to develop novel, safe, and effective strategies for GDM risk reduction [14].

Inulin is a soluble dietary fiber, which is stored in the tubers of a perennial herb Jerusalem artichoke [15, 16]. Due to the specific chemical structure, inulin dietary fiber is not digested in the human mouth, stomach, or small intestine, so that it does not cause increase in blood glucose concentration, but rather prevents sharp changes in blood sugar and protecting islet cells after ingestion, thus known as “natural insulin” for diabetic patients [17]. In 2017, a systematic review of clinical trial results showed that dietary supplementation with inulin reduced biomarkers of metabolic syndrome [18]. Miakiewicz-Has et al. found supplementation with inulin had a negative effect on plasma glucose in both diabetic and non-diabetic rats [19]. In the United States in 2018, the Food and Drug Administration approved inulin as a dietary fiber ingredient used to improve the nutritional value of manufactured food products. Inulin-treated hyperglycemic mice had decreased average daily food consumption, body weight, average daily water consumption and relative liver weight and blood concentrations of TAG, total cholesterol, HDL-cholesterol and fasting blood glucose[20].

Furthermore, inulin has been associated with improved glucose metabolism and reduced risk of GDM [21]. While the mechanisms linking inulin to metabolic health are poorly understood, inulin are known to modify the intestinal microbiome and stimulate production of short-chain fatty acids (SCFAs). SCFAs affect the expression of a number of proteins that have been demonstrated to decrease gut permeability and increase insulin sensitivity [22, 23]. However, the evidence that inulin supplementation should be recommended before or during pregnancy to reduce the risk of GDM is limited [24, 25]. This study was, therefore, carried out to investigate the mechanism and effects of inulin supplementation on glycolipid metabolism and pregnancy outcomes in GDM mice.

Materials and methods

Animals and study design
Six to seven-week-old C57BL/6J mice were purchased from Vital River Laboratory Animal Technology Co., Ltd., (China) and acclimatized to the animal facility for 1 week. Mice were maintained on a 12-h light-dark cycle with free access to food and water. All experiments were performed in accordance with the Animals (Scientific Procedures) Act 1986 and approved by the Ethics Committee of Women’s Hospital of Nanjing Medical University (No.2018-49).

Female mice were fed normal chow diet (NCD group, Research Diets AIN-93G, consisting of 20.3% protein, 63.9% carbohydrate, and 15.8% fat), a high-fat/sucrose diet (HFD) (GDM group, Research Diets D12451, consisting of 19.8% protein, 35.2% carbohydrate, and 45% fat), high-dose inulin supplemented a high-fat/sucrose diet (Inulin-L group, 1.67 g/kg/days via oral gavage ) or low-dose inulin supplemented a high-fat/sucrose diet (Inulin-H group, 3.33 g/kg/days via oral gavage ) for 4 weeks before being mated with age-matched male mice. Upon identification of a copulatory plug, considered to be day 0 of pregnancy (GD0). Mice were euthanized by CO₂ inhalation on GD18 (or equivalent) after fasting for 6 h from 8 AM and blood and tissues were collected. Liver and inguinal fat was quickly collected and kept at − 80 °C.

Measurement of body weight, blood glucose and serum insulin

Body weight, blood glucose and serum insulin were monitored at different time points, including before dietary intervention, after 4 weeks of HFD, and on GD 0, 10, 14 and 18. Blood glucose and insulin levels were determined from tail venipuncture blood samples. Blood glucose concentration was measured immediately using a blood glucose meter and strips (Roche Accu-Chek Active, Mannheim, Germany). The blood samples were then centrifuged at low speed (4 °C, 3000 rpm, 15 min) within 1 h, the supernatant was harvested and stored at − 80 °C for measuring serum insulin level by enzyme linked immune sorbent assay (ELISA; NJJCBIO Co., Ltd, Nanjing, China) according to the manufacturer's instructions. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by the following formula: fasting blood glucose (FBG, mmol/L) × fasting serum insulin (µIU/mL)/22.5. In addition, urine volume and fluid intake were observed daily.

Oral glucose tolerance test

Glucose tolerance was determined by an oral glucose tolerance test (OGTT) on GD 14. Mice were fasted for 6 h with free access to water and received an oral gavage of 20% D-glucose (2 g/kg body weight). Blood samples were collected from the tail vein at 0, 30, 60, 90 and 120 min after glucose administration. Blood glucose levels were measured instantly using methods as mentioned above. Meanwhile, area under the curve (AUC) of blood glucose was calculated [26].
Serum lipid measurement and total AGES
Levels of serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) as well as the concentration of Serum total advanced glycation end products (AGEs) were measured using commercial kits (NJJCBIO Co., Ltd, Nanjing, China) according to the manufacturer’s instructions.

Haematoxylin-eosin staining
Liver and inguinal fat tissues were fixed in 4% paraformaldehyde, decalcified, paraffin-embedded and stored at 4 °C. After tissues were sliced into 4 μm sections, haematoxylin-eosin staining was performed. First, sections were stained with haematoxylin for 5–10 min, immersed in 70% ethanol for 30 min to remove cytoplasm colouring, alkalized with alkaline solution and washed with distilled water for 1 min. Second, sections were stained with eosin for 30–60 s, dehydrated with gradient ethanol, cleared two times with xylene, dried and mounted. Finally, the morphological structures of the liver and inguinal fat tissues were observed under an optical microscope.

RT² profiler PCR array analysis
Total RNA was isolated from the liver samples of NCD group, GDM group and Inulin-H group using Qiagen RNeasy® Mini Kit (QIAGEN, Shanghai, China) according to the manufacturer’s instructions. Single-strand cDNA was synthesized from 1 μg of total RNA by reverse transcription reaction using Qiagen RT² First Strand Kit (QIAGEN, Shanghai, China). The cDNA was mixed with Qiagen PCR RT² SYBR Green Master Mix (QIAGEN, Shanghai, China).

To explore the underlying mechanisms of inulin-induced effects, the expression of 84 genes involved in Glycolipid metabolism including RETN were examined using RT² profiler PCR array (PAMM-006Z-mouse glucose metabolism, QIAGEN, Shanghai, China). Relative quantification of mRNA levels was determined by real-time quantitative PCR using an ABI 7500 RT-PCR machine/Bio-Rad CFX96 Sequence Detector instrument. The quantitative expression of gene was calculated from the cycle threshold (CT) value of each sample in the linear part of the curve using the relative quantification method (2^(-ΔΔCt)) [27]. The samples were analyzed in triplicate and corrected for the selected internal standard which had the smallest standard deviation among the housekeeping genes. Candidate genes were selected from those whose expressions differed greater than twofold or less than twofold, or which differed significantly (p < 0.05) between the GDM group and Inulin-H treatment group.

Quantitative PCR (qPCR) analysis for the candidate genes
The five most differentially-expressed genes between GDM group and Inulin-H group were selected from the RT² profiler PCR array as candidate genes and were analyzed the correlation with FBG further. Specific PCR primers were designed for further quantitative real-time PCR analysis (Takara, Dalian, China) as follows.

**G6pc:** 5' -CGACTCGCTATCTCAAAGTG-3' and 5'-GGCCTTGTCCAAACAGAAT-3'.
**RETN:** 5’-ACAAGACTTCCAATCTGGTGGT-3'Cand 5’-TTCTTCAGCAATGTCCACG-3'.
**Igfbp5:** 5’-CCCTGCGCAGAGGAAAGC-3' and 5’-GGGCCTGGGTGTTGATCC-3'.
**IL10:** 5’-CCCCATTCCTCGTCAAGATC-3' and 5’-TTCTAGCTGGTTGATCC-3'.

Western blot analysis
Liver and inguinal fat tissues were harvested and were homogenized on ice in the presence of protease and phosphatase inhibitors. Homogenates were centrifuged at 12,000×g at 4 °C for 15 min. Protein concentration in supernatants was quantified by the BCA method using bovine serum albumin (BSA) as the standard. Proteins were analyzed by 10% SDS-PAGE and transferred to PVDF membranes that were incubated in 5% non-fat milk at room temperature for 1 h, then incubated with appropriate primary and secondary antibodies: Phospho-IRS-1 (Ser1101) antibody (#2385T, 1:1000 dilution for WB), IRS-1 (D23G12) antibody (#3407T, 1:1000 dilution for WB), p44/42 MAPK (Erk1/2) (137F5) antibody (#4695T, 1:1000 dilution for WB), Phospho-p44/42 MAPK (Thr202/Tyr204) antibody (#4370T, 1:1000 dilution for WB), Akt (pan) antibody (#4685, 1:1000 dilution for WB) and Phospho-Akt (Ser473) antibody (#4060, 1:1000 dilution for WB) were obtained from Cell Signaling Technology, Inc. (MA, USA). Resistin (ab119501, 1:1000 dilution for WB) and GLUT4 antibody (ab33780, 1:1000 dilution for WB) was purchased from Abcam (MA, USA). β-actin (20536-1-AP, 1:5000 dilution for WB) and HRP-conjugated Affinipure Goat Anti-Rabbit (SA00001-2, 1:10,000 for WB) were purchased from Proteintech Group, Inc (IL, USA). Color prestained protein Marker (180-6003) was purchased from Tanon Science and Technology Co., Ltd. (Shanghai, China). Membranes
were washed and proteins were detected by enhanced chemiluminescence (ECL) using a LAS-4000 lumino-image analyzer (Fuji Film, Tokyo, Japan). Bands were digitally scanned and analyzed using ImageJ software (NIH Image, National Institutes of Health, Bethesda, MD, USA).

**Statistical analysis**

All data were calculated as means ± SD and checked using the Kolmogorov-Smirnov (KS) test before further analysis. Statistical significance between two datasets was assessed using the Student’s t-test. Multiple groups were compared using one-way ANOVA followed by Tukey multiple comparison testing. For the repeated measures in case of growth and OGTT results, multivariate ANOVA was performed with a post hoc test using Bonferroni method. A $P$ value of $<0.05$ was considered statistically significant. All statistical tests were performed using GraphPad Prism Version 7.0 (GraphPad Prism Software, Inc. CA, USA).

**Result**

**Changes of body weight and reproductive outcome of pregnant mice**

Body weight was determined at different time points for all groups. As indicated in Fig. 1A, the body weight of GDM group showed an increasing trend after 4 weeks of HFD prior to mating, and a rapid elevation of body weight was found in the mice of GDM group compared to the moderate increase in NCD group and Inulin-H group during peripartum. The weight at GD 18 and total weight gain of GDM (37.88 ± 3.32 g and 15.32 ± 0.86 g) and Inulin-L group (36.28 ± 3.16 g and 14.39 ± 0.97 g) were significantly higher than that of NCD group (34.54 ± 2.42 g and 13.13 ± 0.78 g) and Inulin-H group (33.34 ± 3.80 g and 12.22 ± 0.92 g) (Fig. 1B). After inulin
intervention, the Inulin-H group showed no statistically significant difference in body weight compared with the NCD group (Fig. 1A, B). In addition, the urine volume and fluid intake were increased significantly during mid-to-late pregnancy in GDM mice compared to NCD mice. However, there was no significant change in the mice of Inulin-L or Inulin-H group.

The number, body weight and length of fetal mice in each group were compared. There was no significant difference in the number of fetal mice among groups (Fig. 1C). The average body weight and length of fetal mice born by GDM mothers (1.27±0.17 g and 2.32±0.08 cm) were significantly higher than those by NCD (0.94±0.16 g and 2.23±0.12 cm) and Inulin-H mothers (1.04±0.07 g and 2.19±0.10 cm) (Fig. 1D, E).

**Glucose tolerance test, blood glucose, serum insulin and total AGEs in mice**

We examined the blood glucose and serum insulin in these mice. Blood glucose levels did not differ amongst the groups at the end of 4-week feeding before mating and exhibited a gradual upregulation during pregnancy in the mice of GDM and Inulin-L groups but not NCD or Inulin-H group (Fig. 2A). Moreover, blood glucose, serum insulin and total AGEs on GD 18 were significantly advanced in GDM mice (10.83±0.93 mmol/l, 19.34±1.98 mIU/L and 218±8.6 ng/ml) in contrast to the NCD mice (8.77±0.75 mmol/l, 13.52±1.68 mIU/L and 116±7.8 ng/ml) (Fig. 2C–E). Interestingly, blood glucose levels were deregulated at the end of pregnancy in each group (Fig. 2A), whereas insulin levels were increased in both GDM and Inulin-L mice and showed a more pronounced enhancement in the mice of GDM group (Fig. 2B). After
inulin intervention, the Inulin-H group showed no statistically significant difference in blood glucose, insulin and total AGEs changes compared with the NCD group (Fig. 2C–E).

By performing a glucose tolerance test at the end of 4-week feeding before mating, we found that blood glucose and insulin levels of mice in GDM group indicated a slight increase without statistically significant differences, suggesting HFD for 4 weeks did not cause dramatical changes in either glucose or insulin levels (Fig. 3A, C). Then, we conducted the same test on GD 14. As shown in Fig. 3B, compared with NCD group, the mice in GDM group showed impaired glucose tolerance, as manifested by obviously increased glucose levels after glucose injection ($P < 0.01$, 0, 30, 60, 90 and 120 min). While the blood glucose of Inulin-L and Inulin- H group mice were dramatically lower than those of GDM group throughout the test ($P < 0.01$, Fig. 2G), as were the AUCs (Fig. 3D). All these suggested that inulin treatment could significantly improve the glucose tolerance of GDM mice.

**Effects of inulin on lipid profiles and tissues morphology in mice**

The levels of TG, TG and LDL in GDM group were significantly higher than those in the other three groups, suggesting that HFD could elevate serum lipid levels of GDM mice, while inulin intervention could significantly

---

![Graphs](image.png)

**Fig. 3** Blood glucose (A, C) during oral glucose tolerance test in the four groups after 4 weeks of HFD. Blood glucose (B, D) during oral glucose tolerance test in the four groups on GD 14. Data ($n = 15$) are expressed as the mean ± SD values and analysed by one-way or multivariate ANOVA followed by Tukey’s or Bonferroni’s post-tests: **$P < 0.01$ vs. NCD group; # $P < 0.01$ vs. GDM**

**Fig. 4** Changes of lipid profile (A-D) in mice of different groups on GD 18. Data ($n = 15$) are expressed as the mean ± SD values and analysed by one-way followed by Tukey’s post-tests: **$P < 0.01$ vs NCD group; # $P < 0.05$ vs GDM. Changes of hepatic and adipose morphology (E, F). The hepatic and adipose tissues were stained with HE for morphologic analysis under light microscopy. Morphologic changes of hepatic and adipose cells were observed under at different magnifications field ($\times$ 100 and $\times$ 400).
Fig. 4 (See legend on previous page.)
reduce serum triglyceride, total cholesterol and low-density lipoprotein levels of GDM mice (Fig. 4A, B, D). However, there was no significant difference in serum HDL among groups (Fig. 4C).

This finding was supported by histology, which showed an increase in lipid droplets in hepatic and adipose tissues from mice fed the HFD diet and the HFD diet supplemented with inulin compared to NCD. Hepatic lipid droplets and adipocyte hypertrophy were significantly alleviated in mice from Inulin-L and Inulin-H group compared to GDM group (Fig. 4E and F), suggesting that inulin could attenuate the fat accumulation induced by HFD.

**Effects of inulin on the expression of those genes involved in glycolipid metabolism pathway**

Sixteen genes involved in the glycolipid metabolism were detected with different expressions between Inulin-H group mice and GDM mice in hepatic tissues (Fig. 5A–C). The five most differentially-expressed genes (G6pc, Slc14a2, Igfbp5, RETN, Il10) were validated by qPCR with the specific primers in hepatic and adipose tissues. We found that the five genes’ expressions were consistent with RT² profiler PCR array results, and the consistent results were observed on the housekeeping genes as well. In particular, the expression of RETN was significantly down-regulated after inulin treatment compared to GDM in hepatic (1.10±0.01 vs 4.30±0.60) (Fig. 5D) and adipose tissues (1.17±0.01 vs 15.86±2.10) (Fig. 5E). We next examined the association between RETN relative expression in hepatic and adipose tissues and FBG levels on GD18. We found that increased RETN expression was significantly correlated with increasing fasting glucose (Fig. 5F, G).

**Measurement of alterations of protein expression by western blotting**

Previous studies have shown that RETN played an important role in the regulation of insulin signaling pathway. RETN could induce insulin resistance by inhibiting the phosphorylation of IRS, Akt and ERK 1/2 proteins [28].

Western blotting was used to investigate any changes of RETN and these kinases (IRS, Akt and ERK 1/2) after inulin treatment in mouse liver and adipose tissue. The western blot analysis results showed that the protein level of RETN was consistent with the mRNA results (Fig. 6A–C). The ratio of p-IRS to IRS signal molecule in liver tissue of GDM group was significantly reduced compared to NCD group (Fig. 7A, B). After the ITF-H treatment, the ratios of p-IRS to IRS and p-Akt to Akt in liver tissue and the ratio of p-Akt to Akt in adipose tissue increased significantly (Fig. 7 A, C). Similarly, it was demonstrated that administration of inulin has increased the protein level of GLUT4 (Fig. 8A–C). These results suggested that inulin could enhance the phosphorylation of IRS and Akt signaling molecules and accelerate GLUT 4 translocation to improve glucose and lipid metabolism in GDM mice.

**Discussion**

The recommended diet for glycemic control should be rich in dietary fiber [29]. Inulin is a widely distributed carbohydrate in nature, which is a recognized dietary fiber [30]. In the present study, inulin improved glucose tolerance, reduced insulin resistance, and lowered body weight, serum total AGEs, serum triglyceride, total cholesterol and low-density lipoprotein levels in GDM mice. Moreover, inulin improved the pregnancy outcomes of GDM mice. In addition, a further significant decrease of RETN expression and increase of the phosphorylation level of IRS and Akt signaling molecules in insulin signaling pathway, thereby the increase of GLUT4 expression were observed upon exposure to inulin. Taken together, our study demonstrates a beneficial effect of inulin in the control of gestational diabetes, and this effect is related to the activation of insulin signaling pathway.

GDM is a metabolic disorder that is characterized by hyperglycemia accompanied with insulin resistance. In the present study, the blood glucose level and insulin level were significantly increased in the GDM group mice on GD 18, indicating that GDM was successfully established in these animals [31, 32]. AGEs have been implicated in the pathogenesis of both type 1 and type 2 diabetes [33]. Several studies have shown that AGEs are associated with insulin resistance [34, 35], and can induce low-grade inflammation [36] and pancreatic beta cell dysfunction [37]. Serum total
Fig. 5 (See legend on previous page.)
AGEs on GD 18 were significantly advanced in GDM mice. We also observed disorders of lipid metabolism in GDM mice as evidenced by elevated serum levels of TG, TC and LDL, which is similar to the metabolic profile in the humans with GDM [38]. The therapeutic effects of inulin on metabolic disorders have been extensively reported [39–41]. A previous study showed that oral administration of inulin at 5 g/kg/day for 10 weeks protected the rats from diabetes-induced renal injury [42]. In the present study, we chose the doses of 3.33 and 1.67 g/kg/day to evaluate the potential antidiabetic effects of inulin in mice. The results showed that 4 weeks before mating and throughout pregnancy treatment with inulin relieved the diabetic symptoms as evidenced by reduced blood glucose level and insulin level. However, Farhangi et al. found that inulin significantly reduced the fasting serum glucose level and HbA1C ratio, but had little effect on the insulin level in patients with T2DM [43]. Our results showed that inulin modulated glucose metabolism in a dose-dependent manner, thus we speculate that the differential effects of inulin on insulin may be due to different dosages (10 g/day for T2DM patients in Farhangi et al.'s study). Moreover, we observed a strong hypolipidemic effect of inulin in GDM rats. These results agree with a previous study showing that inulin promoted lipid metabolism by altering the expression of acetyl-CoA carboxylase and the activities of fatty acid synthase and xanthine oxidase [40].

Liver and adipose are major contributors that responsible for lipid and glucose metabolism, and they are sensitive to insulin signal for the regulation of glucose homeostasis [44]. In the pathological conditions of GDM, insulin action is compromised and glucose uptake by these cells were disrupted, resulting in hyperglycemia [45, 46]. In the present study, treatment with chicory inulin could attenuate increased lipid droplet size in retroperitoneal fat tissue and hepatic lipid accumulation induced by HFD.

To explore the underlying mechanisms of inulin induced antidiabetic effects, the expression of 84 genes involved in glucose metabolism were examined. Five candidate genes with most differential-expression following inulin treatment were validated, and they were mainly involved in the glycolysis/gluconeogenesis pathway and participated in different types of metabolism process including glucose metabolic process and gluconeogenesis. Insulin signaling plays a pivotal role in maintaining basic cellular functions such as synthesis and degradation of glycogen, lipids and proteins [47]. In this study, we found that RETN expression was the most down-regulated after inulin treatment, and this down-regulation

Fig. 6 Changes of hepatic and adipose RETN protein expression levels. Representative immunoblot (A) and quantification of RETN (B, C) in the hepatic and adipose tissues of mice from the three groups. Data (n = 15) are expressed as the mean ± SD values and analysed by one-way followed by Tukey’s post-tests: **P < 0.01 vs. NCD group; ##P < 0.01 vs. GDM.
was positive correlated with fasting glucose level in GDM mice. RETN is a pro-inflammatory adipokine that as an influential factor interferes with insulin action, signaling, and glucose metabolism [47–50]. Benomar et al. demonstrated that RETN interfered with normal insulin signaling pathway by inhibiting phosphorylation of IRS (the major downstream target of insulin receptor), Akt, and ERK 1/2 [28]. GLUT4 is the main insulin-responsive glucose transporter which was cloned and studied in several laboratories in 1989. Those studies showed that GLUT4 proteins are translocated to plasma membrane by the action of insulin through the insulin signaling pathway [51]. In this present study, the ratios of p-IRS to IRS and p-Akt to Akt in liver tissue and the ratio of p-Akt to Akt in adipose tissue as well as the expression level of GLUT4 increased significantly after the inulin treatment. The mechanism underlying improvement of glucose and lipid metabolism by inulin was to activate glucose transport through the translocation of GLUT4 which was mediated by insulin signaling pathway repairment due to decreased expression of RETN and enhanced phosphorylation of IRS and Akt in GDM mice (Fig. 9).

The molecular systems assessed in the current study are at the critical interface between cell metabolism; thereby having a strong impact on other physiological parameters, which suggests that insulin can influence a range of cellular processes. In agreement, a large body of literature suggests that many food-derived bioactive compounds, such as Raffinose, aspalathin, curcumin and resveratrol, can positively affect glucose or lipid metabolism, in part by controlling major cellular response mechanisms such as activation of insulin dependent or independent signaling pathways in conditions of metabolic stress [52–55]. This study lays an important foundation for future investigations to inform how the dietary fiber, inulin, modulates the essential genes involved in energy regulation to enhance improve substrate metabolism (the uptake of glucose and palmitate) and enhance ATP (adenosine triphosphate) production in vitro.

In addition to RETN and insulin signaling pathway, some other genes and signaling pathways are also implicated in the regulation of glucolipid metabolism, such as AMP-activated protein kinase (AMPK) and PI3K/AKT pathways [56, 57]. Exploring whether exerts its
glucose-control effects through these pathways, though beyond the scope of our present study, will provide interesting insights into the molecular mechanisms underlying inulin’s hypoglycemic action. Thus, further studies are needed to verify the involvement of other pathways in mediating the anti-diabetic actions of inulin.

**Fig. 8** Changes of hepatic and adipose GLUT4 protein expression levels. Representative immunoblot (A) and quantification of GLUT4 (B, C) in the hepatic and adipose tissues of mice from the three groups. Data (n = 15) are expressed as the mean ± SD values and analysed by one-way followed by Tukey’s post-tests: **P<0.01 vs. NCD group; ##P<0.01 vs. GDM**

**Fig. 9** Presumed mechanism by which inulin alleviated glucose and lipid metabolism disorders in gestational diabetes mellitus mice. The mechanism underlying improvement of glucose and lipid metabolism by inulin was to activate glucose transport through the translocation of GLUT4, which was mediated by insulin signaling pathway repairment due to decreased expression of RETN and enhanced phosphorylation of IRS and Akt in GDM mice. Finally, this signal leads to changes in downstream metabolic functions. GDM: Gestational diabetes mellitus; FBG: Fasting blood glucose; IR: Insulin resistance; AGEs: Advanced glycation end products; TG: Triglycerides; TC: Total cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; RETN: Resistin; IRS: Insulin receptor; Akt: Protein kinase B; ERK 1/2: Extracellular signal-regulated protein kinases 1 and 2; GLUT4: Glucose transporter isoform 4.
Conclusions
In summary, our study demonstrates that inulin could lower blood glucose level and improve glucometabolism. Inulin treatment was associated with reduction in improvement of impaired oral glucose and insulin tolerance, lipid profile, liver structure and function, and it could also promote pregnancy outcomes in gestational diabetic mice. These actions are likely to be mediated via repairment of insulin signaling pathway. Our findings suggest a potential value of inulin as a healthcare supplement for GDM patients. Further studies could include analysis of cellular energy metabolism and other pathways in mediating the anti-diabetic actions of inulin.

Abbreviations
GDM: Gestational diabetes mellitus; SCFAs: Short-chain fatty acids; NCD: Normal chow diet; HFD: High-fat/sucrose diet; FBG: Fasting blood glucose; IR: Insulin resistance; AGEs: Advanced glycation end products; OGTT: Oral glucose tolerance test; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; RETN: Resistin; IRS: Insulin receptor; Akt: Protein kinase B; ERK: Extracellular signal-regulated protein kinases 1 and 2; GLUT4: Glucose transporter isoform 4.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13098-021-00768-8.

Acknowledgements
Not applicable.

Authors’ contributions
MM, YD, PL, GS and XZ designed the experiments; CR and CF performed the experiments; YF and XW analyzed the data; JM, WH and ZD contributed reagents/materials/analysis tools; MM wrote the paper. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81801480), Six Talent Project in Jiangsu Province (WST-119, WSW-120).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The animal experiments were performed according to internationally followed ethical standards and approved approved by the Ethics Committee of Women’s Hospital of Nanjing Medical University (No. 2018-49).

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

Received: 18 September 2021 Accepted: 9 December 2021

References
1. Association AD. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019, 42:S13-S28.
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
3. Martis R, Crowther CA, Shepherd E, Alsweiler J, Downie MR, Brown J. Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2018,8:CD012327.
4. Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA, Duncan BB, Schmidt MI. Gestational diabetes and pregnancy outcomes: a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23.
5. Wroblewska-Seniuk K, Wender-Ozegowska E, Szczapa J. Long-term effects of diabetes during pregnancy on the offspring. Pediatr Diabetes. 2009;10:432–40.
6. Woo Baidal JA, Locks LM, Cheng ER, Blake-Lamb TL, Perkins ME, Taveras EM. Risk Factors for Childhood Obesity in the First 1,000 Days: A Systematic Review. Am J Prev Med. 2016;50:761–79.
7. Hammoud NM, Visser GHA, van Rossem L, Biesma DH, Wit JM, de Valk HW. Long-term BMI and growth profiles in offspring of women with gestational diabetes. Diabetologia. 2018;61:1037–45.
8. Appiah D, Schreiner PJ, Gomerson JP, Konyet SH, Jacobs DR Jr, Nwabuo CC, Ebong IA, Whitham HK, Goff DC Jr, Lima JA, et al. Association of Gestational Diabetes Mellitus With Left Ventricular Structure and Function: The CARDIA Study. Diabetes Care. 2016;39:400–7.
9. Lowe WL. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose. Metabolism. 2019;42:372–80.
10. Chieffani E, Arcidiacono B, Toff D, Brunetti A. Gestational diabetes mellitus: an updated overview. J Endocrinol Invest. 2017;40:899–909.
11. Lappas M. Activation of inflammasomes in adipose tissue of women with gestational diabetes. Mol Cell Endocrinol. 2014;382:74–83.
12. Toljic M, Eagic A, Munjas J, Karadzov Orlic N, Mikovanovic Z, Radenkovic A, Vucelic J, Jokic I. Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension. Reprod Toxicol. 2017;71:55–62.
13. Page KA, Buchanan TA. The vicious cycle of maternal diabetes and obesity: moving from “what” to “how” and “why.” J Pediatr. 2011;158:S72–3.
14. Plows JF, Ramos Nieves JM, Budin F, Mace K, Reynolds CM, Vickers MH, Silva-Zolezzi I, Baker PN, Stanley JL. The effects of myo-inositol and probiotic supplementation in a high-fat-fed preclinical model of glucose intolerance in pregnancy: Br J Nutr. 2020;123:S16–28.
15. Petrovsky N, Cooper PD. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015;33:5920–6.
16. Shaib M, Shehzad A, Omar M, Rakha A, Raza H, Sharif HR, Shakeel A, Ansari I, Niazi S. Inulin: Properties, health benefits and food applications. Carbohydr Polym. 2016;147:444–54.
17. Jackson KG, Taylor GR, Clohessy AM, Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br J Nutr. 1999;82:23–30.
18. Liu F, Prabhakar M, Ju J, Li Q, Zou HW; Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71:9–20.
19. Misiaıkiewicz-Has K, Maciejewska-Markiewicz D, Rzeszotek S, Pilutin A, Kolasa A, Szumilas P, Stachowksa E, Wieszniewska B. The obscure effect of tribulus terrestris saponins plus inulin on liver morphology, liver fatty acids, plasma glucose, and lipid profile in SD rats with and without induced type 2 diabetes mellitus. Int J Mol Sci. 2021;22:9.
Shao T, Yu Q, Zhu T, Liu A, Gao X, Long X, Liu Z. Inulin from Jerusalem artichoke tubers alleviates hyperglycaemia in high-fat-diet-induced diabetes mice through the intestinal microflora improvement. Br J Nutr. 2020;123:308–18.

21. Ahmadi S, Iamlim M, Tajabadi-Ebrahimi M, Jafari F, Asemi Z. The effects of sybionic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2016;116:1394–401.

22. Taylor BL, Woodfall GE, Sheedy KE, O'Riley ML, Rainbow KA, Bramwell EL, Kellow NJ. Effect of probiotics on metabolic outcomes in pregnant women with gestational diabetes: a systematic review and meta-analysis of randomised controlled trials. Nutrients. 2017;9:789.

23. Tilg H, Moschen AR. Food, immunity, and the microbiome. Gastroenterol. 2015;148:1107–19.

24. Rogozinska E, Chamillard M, Hitman GA, Khan KS, Thangaratinam S. Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies. PLoS ONE. 2015;10:e0115526.

25. Plows JF, Reynolds CM, Vickers MH, Baker PN, Stanley JL. Nutritional supplementation for the prevention and/or treatment of gestational diabetes mellitus. Curr Diab Rep. 2019;19:73.

26. Torimoto K, Okada Y, Tanaka Y, Matsuoka A, Hirota Y, Ogawa W, Saiyo H, Kunihara I, Itoh H, Inada S, Koga M. Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocr J. 2020;67:509–13.

27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(Delta Delta C(T)) Method. Methods. 2001;25:402–8.

28. Benomar Y, Gertler A, De Lacy P, Crépin D, Ould Hamouda H, Riffault L, Taouis M. Central resistin overexpression induces insulin resistance through Toll-like receptor 4. Diabetes. 2013;62:102–14.

29. Kurihara I, Itoh H, Inada S, Koga M. Usefulness of the index calculated as product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocr J. 2020;67:509–13.

30. Cai G, Yu H, Liu L, Lu T, Ji J, Ye L, Ze B, Lao B, Ma W, Xiao R, Yang Y. Milk-Powder Co-Supplemented with Inulin and Resistant Dextrin Improves Glycemic Control and Insulin Resistance in Elderly Type 2 Diabetes Mellitus: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Mol Nutr Food Res. 2018;62:e1800865.

31. Skovas M. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014;5:349–58.

32. Islam MS, du Loooots T. Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol. 2009;31:249–72.

33. Kellow NJ, Coughlan MT, Savage GS, Reid CM. Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. BMC Endocr Disord. 2014;14:55.

34. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizuguchi M, Imazumi T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther. 2012;30:42–8.

35. Tan KC, Shiu SW, Wong Y, Tam X. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev. 2011;27:488–92.

36. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products on hyperglycaemia, hyperlipidaemia and lecithin cholesterol acyltransferase activity, in high-fat diet-induced type 2 diabetic rats. Br J Nutr. 2016;115:6–13.

37. Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F, Van Obberghen E. Impact of dietary fiber consumption on insulin resistance and the prevention of type 2 diabetes. J Nutr. 2018;148:7–12.

38. Cai G, Yu H, Liu L, Lu T, Ji J, Ye L, Ze B, Lao B, Ma W, Xiao R, Yang Y. Milk-Powder Co-Supplemented with Inulin and Resistant Dextrin Improves Glycemic Control and Insulin Resistance in Elderly Type 2 Diabetes Mellitus: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Mol Nutr Food Res. 2018;62:e1800865.

39. Lin W, Liu C, Yang H, Wang W, Ling W, Wang D. Chicory, a typical vegetable in Mediterranean diet, exerts a therapeutic role in established atherosclerosis in apolipoprotein E-deficient mice. Mol Nutr Food Res. 2015;59:1803–13.

40. Lin Z, Zhang B, Liu X, Jin R, Zhu W. Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets. J Med Food. 2014;17:1214–21.

41. Nishimura M, Okhawara T, Kanayama T, Kitagawa K, Nishimura H, Nishihira J. Effects of the extract from roasted chicory (Cichorium intybus L) root containing inulin-type fructans on blood glucose, lipid metabolism, and fecal properties. J Tradit Complement Med. 2015;5:161–7.

42. Ning C, Wang X, Gao S, Mu J, Wang Y, Liu S, Zhu J, Meng X. Chicory inulin ameliorates type 2 diabetes mellitus and suppresses JNK and MAPK pathways in vivo and in vitro. Mol Nutr Food Res. 2017;61:9012.

43. Farhangi MA, Jadav AZ, Dehghan P. The effect of enriched chicory inulin on liver enzymes, calcium homeostasis and hematological parameters in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial. Prim Care Diabetes. 2016;10:265–71.

44. Zhao W, Li A, Feng X, Hou T, Liu K, Liu B, Zhang N. Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 2016;28:1401–11.

45. Hajiaghajipour P, Khallipourfarshab M, Arya A. Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus. Int J Biol Sci. 2015;11:508–24.

46. Stanford KJ, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. Adv Physiol Educ. 2014;38:308–14.

47. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.

48. Benomar Y, Taouis M. Molecular mechanisms underlying obesity-induced hypothalamic inflammation and insulin resistance: pivotal role of resistin/TLR Pathways. Front Endocrinol (Lausanne). 2019;10:140.

49. Derosa G, Catena G, Gaudio G, D’Angelo A, Maffulli P. Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markEns in the progreSSion of diabetes6 in obese paiTeNts (The RESISTIN trial). Cytokeine. 2020;127:1549447.

50. Nemes A, Homoki JR, Kiss R, Hegedüš C, Kovács D, Peti B, Galf F, Stündl L, Szołlässy Z, Remenyik J. Effect of anthocyanin-rich tart cherry extract on inflammatory mediators and adipokines involved in type 2 diabetes in a high fat diet induced obesity mouse model. Nutrients. 2019;11:89234.

51. Sayem ASM, Arya A, Karimian H, Krishnasamy N, Ashok Hasamni A, Hossain CF. Action of phytochemicals on insulin signaling pathways accelerating glucose transporter (GLUT4) protein translocation. Molecules. 2018;23:18.

52. Muthukumaran P, Thiyagarajan G, Arun Babu R, Lukhmi BS. Raffinose from Costus spicatus attenuates lipid synthesis through modulation of PPAR/SREBP1c and improves insulin sensitivity through SREBP1C. Chem Biol Interact. 2018;284:80–9.

53. Johnson R, Beer D, Dludla PV, Ferreira D, Muller CJF, Joubert E. Aspalathin from Rooibos (Aspalathus linearis): A Bioactive C-glucosyl Dihydrochalcone with Potential to Target the Metabolic Syndrome. Planta Med. 2014;80:593–603.

54. Nasiri H, Baradaran A, Shirzad H, Rafieian-Kopaei M. New concepts in nutraceuticals as alternative for pharmaceuticals. Int J Prev Med. 2014;5:1487–99.

55. Nyambyama TM, NKambule BB, Mazibuko Mbege SE, Mxinwa V, Mokgalaboni K, Orlando P, Silvestri S, Louw J, Tiao L, Dludla PV. A meta-analysis of the impact of resveratrol supplementation on markers of renal function and blood pressure in type 2 diabetic patients on hypoglycemic therapy. Molecules. 2020;25:9.

56. Wang S, Xu J, Song P, Volletot B, Zou MH. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes. 2009;58:1893–901.

57. Bai D, Wu Q, Zeng C, Zhang J, Cao L, Xiao Z, Yang M. The effect of Liwue Ohunga decoction on PI3K/Akt signaling pathway in liver of type 2 diabetes mellitus (T2DM) rats with insulin resistance. J Ethnopharmacol. 2016;192:382–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.